Cite
The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma.
MLA
Tomotaka Yazaki, et al. “The Simultaneous Onset of Pancreatitis and Colitis as Immune-Related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma.” Internal Medicine, vol. 61, no. 10, May 2022, pp. 1485–90. EBSCOhost, https://doi.org/10.2169/internalmedicine.7911-21.
APA
Tomotaka Yazaki, Ichiro Moriyama, Hiroshi Tobita, Hiroki Sonoyama, Eiko Okimoto, Akihiko Oka, Yoshiyuki Mishima, Naoki Oshima, Kotaro Shibagaki, Kousaku Kawashima, Norihisa Ishimura, Taichi Nagami, Riruke Maruyama, Hiroaki Shiina, & Shunji Ishihara. (2022). The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. Internal Medicine, 61(10), 1485–1490. https://doi.org/10.2169/internalmedicine.7911-21
Chicago
Tomotaka Yazaki, Ichiro Moriyama, Hiroshi Tobita, Hiroki Sonoyama, Eiko Okimoto, Akihiko Oka, Yoshiyuki Mishima, et al. 2022. “The Simultaneous Onset of Pancreatitis and Colitis as Immune-Related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma.” Internal Medicine 61 (10): 1485–90. doi:10.2169/internalmedicine.7911-21.